[TB Alliance] NEW YORK (August 14, 2019)—Pretomanid, a novel compound developed by the non-profit organization TB Alliance, was approved by the U.S. Food & Drug Administration (FDA) today for treating some of the most drug-resistant forms of tuberculosis (TB).1 The new drug was approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD pathway) […] Continue reading ->
The Global Innovation Index 2019 was released today with an overarching theme of “Creating Healthy Lives – The Future of Medical Innovation.” In addition to ranking countries according to their innovation performance on 80 indicators, this year’s Index also analyses the medical innovation landscape, and how emerging innovations, such as artificial intelligence (AI), genomics, and […] Continue reading ->